Blueprint Medicines reports Q4 EPS (79c), consensus (71c)

Reports Q4 revenue $144.1M, consensus $145.18M. “We are entering 2025 in the strongest position we have ever been in as a company with a focus on driving growth and innovation through operational excellence. AYVAKIT is a medicine that is changing patients’ lives, and the SM market is larger and growing faster than we originally expected. Our 2025 guidance of $680M-$710M represents robust growth, putting AYVAKIT firmly on track to achieve $2B in revenue by 2030. With the larger potential SM franchise peak opportunity of $4B, we have a plan to drive innovation in the treatment of SM with elenestinib as we move beyond symptom control to disease modification in the HARBOR registration study, building a durable SM franchise that we anticipate will grow throughout the next decade,” said CEO Kate Haviland. “Our next potential blockbuster opportunity, BLU-808, is also coming into focus with the healthy volunteer data reported last month. BLU-808 demonstrated a best-in-class profile for an oral wild-type KIT inhibitor enabling our differentiated approach to modulating mast cell activity across thousands of patients with mast-cell-mediated allergic and inflammatory diseases. Altogether, our portfolio represents a unique set of assets, targeting fundamental mast cell biology, that will drive durable and diversified growth over the next decade with significant operating leverage.”